KR890001564A - 약학적 투여 단위 - Google Patents

약학적 투여 단위 Download PDF

Info

Publication number
KR890001564A
KR890001564A KR1019880008290A KR880008290A KR890001564A KR 890001564 A KR890001564 A KR 890001564A KR 1019880008290 A KR1019880008290 A KR 1019880008290A KR 880008290 A KR880008290 A KR 880008290A KR 890001564 A KR890001564 A KR 890001564A
Authority
KR
South Korea
Prior art keywords
phase
dosage
dosage unit
dosage units
formulation
Prior art date
Application number
KR1019880008290A
Other languages
English (en)
Other versions
KR950010156B1 (en
Inventor
조세프 윌헬름 마리탁스 람버트
Original Assignee
에이.지.제이.베르메렌 에이.디.도우마
악조 엔.브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이.지.제이.베르메렌 에이.디.도우마, 악조 엔.브이 filed Critical 에이.지.제이.베르메렌 에이.디.도우마
Publication of KR890001564A publication Critical patent/KR890001564A/ko
Application granted granted Critical
Publication of KR950010156B1 publication Critical patent/KR950010156B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음

Description

약학적 투여 단위
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 활성성분으로 0.5-2.5mg의 17β-에스트라디올 및 100-300μg의 데소게스트렐을 함유하는 갱년기 증상 및 특히 골소증을 치료 또는 예방하기 위한 경구 투여용 약제 단위.
  2. 제1항의 몇가지 투여 단위를 함유하는 약제.
  3. 제2항에 있어서, 제제가 다른 투여 단위를 포함하지 않는 것을 특징으로 하는 약제.
  4. 제2항에 있어서, 제제가 특정 서열의 최소한 22투여단위를 함유하며, 최소한 두상으로 이루어졌으며 첫 번째 상의 각 투여 단위는 활성성분으로 17β-에스트라디올을 함유하며, 두 번째 상의 각 투여 단위는 제1항 또는 제2항에 의한 투여 단위로서 첫 번째 상은 최소한 11 및 두 번째 상은 11-15의 연속적인 투여 단위로 이루어진 제제를 특징으로 하는 약제.
  5. 제4항에 있어서, 투여 단위의 수가 22-30이며 첫 번째 상이 11-15의 연속적인 투여 단위로 구성된 것을 특징으로 하는 약제.
  6. 제4항 또는 제5항에 있어서, 제제가 두가지 상, 즉 14의 투여 단위를 포함하는 첫 번째 및 두 번째 상으로 구성됨을 특징으로 하는 약제.
  7. 제4항 또는 제5항에 있어서, 첫 번째 및 두 번째 상이 12투여단위를 함유하며, 제제가 또한 4위약 투여단위로 이루어진 세 번째 상을 포함하는 것을 특징으로 하는 약제.
  8. 제2항 내지 제7항중 어느 한항에 있어서, 17β-에스트라디올의 양이 17β-에스트라디올이 존재하는 각 투여 단위에 있어서 동일함을 특징으로 하는 약제.
  9. 제2항 내지 제8항중 어느 한 항에 있어서, 데소케스트렐의 양이 데소게스트렐이 존재하는 각 투여 단위에 있어서 동일함을 특징으로 하는 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR88008290A 1987-07-06 1988-07-05 Pharmaceutical dosage unit for the prevention or treatment of climacteric complaints KR950010156B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8701586 1987-07-06
NL8701586 1987-07-06

Publications (2)

Publication Number Publication Date
KR890001564A true KR890001564A (ko) 1989-03-27
KR950010156B1 KR950010156B1 (en) 1995-09-11

Family

ID=19850262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR88008290A KR950010156B1 (en) 1987-07-06 1988-07-05 Pharmaceutical dosage unit for the prevention or treatment of climacteric complaints

Country Status (12)

Country Link
US (1) US4914089A (ko)
EP (1) EP0300523B1 (ko)
JP (1) JPS6429314A (ko)
KR (1) KR950010156B1 (ko)
AT (1) ATE66149T1 (ko)
AU (1) AU611168B2 (ko)
CA (1) CA1313622C (ko)
DE (1) DE3864210D1 (ko)
DK (1) DK376188A (ko)
ES (1) ES2024010B3 (ko)
GR (1) GR3003104T3 (ko)
ZA (1) ZA884418B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IL113816A (en) 1994-06-08 1998-12-06 Akzo Nobel Nv Pharmaceutical preparations containing desogestral, their preparation and use
IL128818A0 (en) * 1998-03-12 2000-01-31 Akzo Nobel Nv Making dosage units using low shear granulation
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
JP2006522833A (ja) * 2003-04-11 2006-10-05 バー・ラボラトリーズ，インコーポレイテッド エストロゲンおよびプロゲスチンの投与法
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
USD731568S1 (en) * 2013-08-01 2015-06-09 Sejong Pharmatech Co., Ltd. Compression molding machine for tablets
USD741386S1 (en) * 2013-09-13 2015-10-20 Carefusion Germany 326 Gmbh Machine for packaging dosed quantities of solid drug portions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6615481A (ko) * 1966-11-02 1968-05-03
DE2645307A1 (de) * 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
GB8617560D0 (en) * 1986-07-18 1986-08-28 Raychem Gmbh Cable connector

Also Published As

Publication number Publication date
EP0300523B1 (en) 1991-08-14
KR950010156B1 (en) 1995-09-11
ES2024010B3 (es) 1992-02-16
JPS6429314A (en) 1989-01-31
AU611168B2 (en) 1991-06-06
DE3864210D1 (de) 1991-09-19
ATE66149T1 (de) 1991-08-15
DK376188A (da) 1989-01-07
DK376188D0 (da) 1988-07-06
AU1866888A (en) 1989-01-12
EP0300523A1 (en) 1989-01-25
ZA884418B (en) 1990-02-28
US4914089A (en) 1990-04-03
GR3003104T3 (en) 1993-02-17
CA1313622C (en) 1993-02-16

Similar Documents

Publication Publication Date Title
KR890001564A (ko) 약학적 투여 단위
ATE93728T1 (de) Behandlung von stoerungen in der postmenopause.
NO953874L (no) Farmasöytisk preparat inneholdende lipofile legemidler
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
KR920011514A (ko) 프로게스토겐만을 함유하는 피임제
RU94040855A (ru) Фармацевтическая композиция на основе эмульсии масло в воде для местного применения, содержащая ароматическое активное вещество
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
UA41401C2 (uk) Фармацевтичний контрацептивний комбінований препарат
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
KR970061244A (ko) 치매 치료용 약학 조성물
WO1994002103A3 (de) Ovulationshemmendes mittel zur hormonalen kontrazeption
DK0437294T3 (da) Orale farmaceutiske præparater i enhedsdosisform
KR970706004A (ko) 호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies)
KR890009407A (ko) 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위
DE3263832D1 (en) Gallium chloride, an anti-cancer drug
KR890004705A (ko) 항바이러스성 제제
RU2449796C9 (ru) Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
FR2374044A1 (fr) Agent anti-diabetique oral contenant une sulfonyluree et une kinine
RU2000115313A (ru) Схемы приема гестаген-анти-гестагена
KR910007514A (ko) 다상 피임 제제
KR900017599A (ko) 종양 치료용 약학 조성물
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020903

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee